Adam Crystal sold $661k of TNGX
President, R&D at Tango Therapeutics, Inc.. 27,000 shares at an average of $24.47, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +20RolePresident
- +20Trade size$661k at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-414500, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +27,000 | $5.20 | $140k | 142,743 | 7 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -26,400 | $24.45 | $646k | 116,343 | 7 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $25.32 | $15k | 115,743 | 7 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,000 | $0.00 | $0 | 233,040 | 7 d ago |
Related signals
Other insiders at Tango Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Tango Therapeutics, Inc. | Jessica Newcomb Principal Accounting Officer | $199k 8,200 shares | -12% | |
| 9Weak | Tango Therapeutics, Inc. | Adam Crystal President, R&D | $604k 27,000 shares | -19% | |
| 30Weak | Tango Therapeutics, Inc. | Douglas Barry General Counsel | $16k 5,330 shares | -7% | |
| 42Moderate | Tango Therapeutics, Inc. | Daniella Beckman Chief Financial Officer | $25k 8,232 shares | -5% | |
| 36Weak | Tango Therapeutics, Inc. | Adam Crystal See Remarks | $44k 14,283 shares | -8% | |
| 33Weak | TNGXbuy Tango Therapeutics, Inc. | Mace Rothenberg director | $74k 20,000 shares | +178% | |
| 50Moderate | Tango Therapeutics, Inc. | EcoR1 Capital, LLC owner | $8.4M 2,700,000 shares | -20% | |
| 51Moderate | Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $9.7M 3,080,000 shares | -46% | |
| 41Moderate | Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $4.3M 633,000 shares | -9% | |
| 38Weak | TNGXsell Tango Therapeutics, Inc. | Boxer Capital Management, LLC other | $6.1M 875,000 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.